http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005017522-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d8e2ecb1fe87598e2fb1d0731bc2c4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff47a38098ebe8bf114b8bbad7775dfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abe5313e7085eeffb6d1c88100574b23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de9fe6d91a2eaa03fac21ef76a347e61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75ca6c5a2ea51cbf963f5018a6bd4880
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ec3c11ce4de28fe94adaa77cc1dfaf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a255eb5981e4ffb8414a5a55c7334cd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d31a20a5dce845ee95e54e6e0eed8f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6875e31d3d393d1f03d699a9323c7311
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f50b73310ac7c4a6ddc97a0163eed472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eeaa0d37000c04cd1196ee2b7d9719ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e5d6a3311faa032ab712503136308f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30d5a240ea7e49a4f6cdc9f5aa8b3c4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dfb3f4b7a8b17b0c799a513144ed47f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7546dd72b8ffc58e290301d01e87381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9a92abee66bc57be443f3dea5af6249
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_571fa5ab705d4eb8e779aa0ebd359352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4df29206f51d335929c08bb08b0cba0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d578fc53529d3d11d117db775d265cd
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0004
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N1-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
filingDate 2004-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eee429df10b0d1cf9853c0e4b57402fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6981e839246b238654fe1b14c48d369
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47037d807279b5afe23670923b2a9dc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1186378c1e2273eea19101b934af47fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2605bbb780ead7730ad287a85a9a5201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_028e248b7002350a0178d7113e4d8d7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cda66b9e70364151318404294fdc87fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97a7070413fe8114a9391e32b0fabf00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_479834af5eaa97a22b35476899959272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6ccedde9e3fbe524c4863f3233a0f74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33280c15efe8ca032900c7ad40598105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e47de1a14cc002a7f7dabf7073e2962b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12825f67785582737b669df553851262
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c4b56369ad34b830288ca4aff2fe5e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a04a5baabde9b4540c23d2ab7948963f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edea3a14eed4fd9de48294e11a0a6847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d997537a54a0249a783cfd4dca525d73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7eb23c60f3a3bf455950db49a5185cf
publicationDate 2005-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005017522-B1
titleOfInvention Method for in vivo determination on tested animals of the efficient concentration of deuterium depleted water for cancer therapy
abstract As per invention embodiment, the method provides Deuterium Depleted Water administering to tested animals before and after tumoral grafting with animal grafts and it takes the following steps: A) Deuterium Depleted Water administering to Wistar outbred rats by diet, with concentrations of 25 ppm D2, 60 ppm D2, and 100 ppm D2, over a period of 60 days, simultaneously to dieting a control group of animals with water having 150 ppm content of Deuterium (tap water), over the same period of time. B) Viability determination for the tumor cells to be grafted, using tripan blue C) Grafting of the animals in the experimental group and the control animals in the 60th day, subcutaneous, with 1 x 107 malign tumor cells in 0.5 cc of normal saline solution of 256 Walker sarcoma (the solid tumor), and T8 Guérin lymphotropic epitelioma (the solid tumor) both of them having cells with a viability over 98%. D) Continuously and long-term administering, by diet, of Deuterium Depleted Water, with concentrations of 25 ppm, 60 ppm, 100 ppm Deuterium, period over which the followings are to be done: a. Starting with the 4th post-graft day the tumor nodules measurement and examination is performed on each 2-3 days; b. Monitoring of animals' physiological condition by weekly weighing, monitoring their food and water consumption, notifying the toxic condition occurrence c. After 60 days, when all the animals in control group are dead, preferable between the 160th and 200th day after graft, the effect produced by administering of established concentrations of Deuterium Depleted Water is observed on the surviving animals homeostasis from experimental groups, respectively the way how humoral immune system and cellular immune system of these animals has been influenced, by performing of a series of examination on immunological condition of the animals, namely: leucocytes formula test to establish lymphocytes and blastic cells levels; hematopoietic marrow tests to establish the plasmocytes and NK-K cells levels. Also, was established the level of the competent immunologic cells in the lymph nods of the tumoral graft zona. E) Determination of efficient concentration of Deuterium Depleted Water for tested surviving animals depending on new homeostasis occurrence, and on the results obtained related to, tumoral regression, as well as on cancer curing cases. This method determines the 60 ppm concentration of Deuterium Depleted Water to be the most efficient for cancer therapy and prophylaxis by continuously and long-term administering of this type of water in daily diet.
priorityDate 2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426095025
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5479131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559591
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1476581
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1476581

Total number of triples: 62.